HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Takeshi Osonoi Selected Research

miglitol (Glyset)

3/2021S100 Genes are Highly Expressed in Peripheral Leukocytes of Type 2 Diabetes Mellitus Patients Treated with Dietary Therapy.
12/2016Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
9/2014Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients.
6/2014Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
12/2010The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Takeshi Osonoi Research Topics

Disease

35Type 2 Diabetes Mellitus (MODY)
04/2022 - 04/2010
13Atherosclerosis
09/2021 - 02/2011
13Cardiovascular Diseases (Cardiovascular Disease)
01/2021 - 02/2011
9Hypoglycemia (Reactive Hypoglycemia)
01/2021 - 12/2010
8Hyperglycemia
04/2022 - 01/2014
6Carotid Artery Diseases
01/2020 - 04/2010
4Diabetic Retinopathy (Retinopathy, Diabetic)
01/2021 - 07/2010
4Albuminuria
01/2021 - 02/2016
4Body Weight (Weight, Body)
11/2020 - 03/2016
4Diabetic Nephropathies (Diabetic Nephropathy)
01/2020 - 01/2013
2Diabetes Mellitus
09/2021 - 12/2016
2Hyperkalemia
02/2021 - 12/2020
2Weight Gain
12/2017 - 03/2014
1Chronic Disease (Chronic Diseases)
02/2021
1Hypertension (High Blood Pressure)
01/2021
1Chronic Renal Insufficiency
11/2020
1Myocardial Infarction
10/2019
1Dementia (Dementias)
10/2019
1Fibrosis (Cirrhosis)
01/2019
1Non-alcoholic Fatty Liver Disease
01/2019
1Inflammation (Inflammations)
10/2018
1Type 1 Diabetes Mellitus (Autoimmune Diabetes)
09/2018
1Insulin Resistance
03/2018
1Obesity
12/2016
1Arteriosclerosis
03/2015
1Chronic Kidney Failure (Chronic Renal Failure)
01/2014
1Edema (Dropsy)
10/2010

Drug/Important Bio-Agent (IBA)

14Glucose (Dextrose)FDA LinkGeneric
09/2021 - 12/2010
8Insulin (Novolin)FDA Link
01/2021 - 12/2010
7GlucosidasesIBA
03/2021 - 12/2010
7Dipeptidyl-Peptidase IV InhibitorsIBA
01/2020 - 01/2013
7Sitagliptin Phosphate (Januvia)FDA Link
01/2018 - 03/2014
5Hypoglycemic Agents (Hypoglycemics)IBA
04/2022 - 03/2016
5miglitol (Glyset)FDA Link
03/2021 - 12/2010
4Metformin (Glucophage)FDA LinkGeneric
04/2022 - 12/2016
4AcarboseFDA LinkGeneric
04/2022 - 12/2010
46- ((4- ethylphenyl)methyl)- 3',4',5',6'- tetrahydro- 6'- (hydroxymethyl)spiro(isobenzofuran- 1(3H),2'- (2H)pyran)- 3',4',5'- triolIBA
09/2021 - 10/2017
4alogliptinIBA
11/2019 - 01/2013
3SodiumIBA
09/2021 - 10/2010
3Sodium-Glucose Transporter 2 InhibitorsIBA
09/2021 - 10/2017
3Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
01/2021 - 09/2018
3LiraglutideFDA Link
11/2020 - 01/2014
3Blood Glucose (Blood Sugar)IBA
01/2020 - 07/2014
3LipidsIBA
03/2018 - 02/2011
2sodium zirconium cyclosilicateIBA
02/2021 - 12/2020
2HDL CholesterolIBA
01/2021 - 02/2011
2Triglycerides (Triacylglycerol)IBA
01/2021 - 12/2010
2CholesterolIBA
01/2021 - 12/2010
2Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA
01/2020 - 06/2014
2Sodium-Glucose Transport ProteinsIBA
01/2020 - 01/2019
2CanagliflozinIBA
12/2019 - 10/2018
2Biomarkers (Surrogate Marker)IBA
10/2018 - 03/2014
2Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
06/2015 - 07/2010
2voglibose (Basen)IBA
09/2014 - 12/2010
2Monocyte Chemoattractant ProteinsIBA
09/2014 - 07/2010
2Pioglitazone (Actos)FDA Link
10/2010 - 04/2010
1Messenger RNA (mRNA)IBA
03/2021
1CationsIBA
02/2021
1Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2021
1HDL LipoproteinsIBA
01/2021
1Antihypertensive Agents (Antihypertensives)IBA
01/2021
1PotassiumIBA
12/2020
1CreatinineIBA
11/2020
1Glucagon (Glukagon)FDA Link
12/2019
1Peptides (Polypeptides)IBA
12/2019
1trelagliptinIBA
11/2019
1Ferritins (Ferritin)IBA
01/2019
11,5- anhydro- 1- (5- (4- ethoxybenzyl)- 2- methoxy- 4- methylphenyl)- 1- thioglucitolIBA
01/2019
1Serum AlbuminIBA
01/2019
1Collagen Type IV (Type IV Collagen)IBA
01/2019
18-Hydroxy-2'-DeoxyguanosineIBA
10/2018
1AlbuminsIBA
10/2018
1semaglutideIBA
01/2018
1VildagliptinIBA
12/2017
1Alanine Transaminase (SGPT)IBA
01/2017
1LeptinIBA
12/2016
1anagliptinIBA
12/2016
1Glucagon-Like Peptide 1 (GLP 1)IBA
12/2016
1gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA
02/2016
1HydrogenIBA
03/2015
1Oxidants (Oxidizing Agents)IBA
03/2015
1Hemoglobins (Hemoglobin)IBA
01/2015
1Plasminogen Activators (Plasminogen Activator)IBA
09/2014
1ChemokinesIBA
09/2014
1Fatty Acid-Binding ProteinsIBA
09/2014
1mitiglinideIBA
07/2014
1Proteins (Proteins, Gene)FDA Link
06/2013
1AdiponectinIBA
02/2012
1oxidized low density lipoproteinIBA
02/2011
1Lipoproteins (Lipoprotein)IBA
02/2011
1CytokinesIBA
12/2010
1C-Reactive ProteinIBA
12/2010
1Hemoglobin AIBA
12/2010
1SaltsIBA
10/2010
1Pharmaceutical PreparationsIBA
04/2010

Therapy/Procedure

14Therapeutics
04/2022 - 03/2014
11Glycemic Control
04/2022 - 01/2013
1Drug Therapy (Chemotherapy)
03/2021
1Aftercare (After-Treatment)
11/2020
1Renal Dialysis (Hemodialysis)
01/2014